From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)
Post chemotherapy
N
%
Irinotecan-based regimen
54
60.7
Oxaliplatin-based regimen
16
18.0
Chemotherapy with bevacizumab
37
41.6
Chemotherapy with cetuximab
32
36.0
Chemotherapy with panitumumab
21
23.6